Clinical trial
A Study of LY317615 in Patients With Brain Tumors
NCT00190723 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190723 |
|---|---|
| Title | A Study of LY317615 in Patients With Brain Tumors |
| Official title | A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Glioma |
| Intervention type | Drug |
| Interventions | Enzastaurin |
| Enrollment | 120 |
| Start date | Oct 1, 2002 |
| Completion | Dec 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: